Amendment: SEC Form S-1/A filed by Locust Walk Acquisition Corp.

4 - LightWave Acquisition Corp. (0002061379) (Issuer)

10-Q - LightWave Acquisition Corp. (0002061379) (Filer)

NT 10-Q - LightWave Acquisition Corp. (0002061379) (Filer)

SCHEDULE 13G/A - LightWave Acquisition Corp. (0002061379) (Subject)

Dallas, TX, June 26, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the closing of its initial public offering of 21,562,500 units at an offering price of $10.00 per unit. This includes the exercise in full by the underwriters of their over-allotment option to purchase up to an additional 2,812,500 units. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one Class A ordinary share at $11.50 per share. The units are listed on the Nasdaq Global Market ("N

Dallas, TX, June 24, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 18,750,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant, which becomes exercisable 30 days after the completion of the Company's initial business combination, will entitle the holder thereof to purchase one Class A ordinary share at $11.50 per share. The units are expected to trade on the Nasdaq Stock Market LLC ("Nasdaq") und

SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ:LWAC) ("LWAC" or the "Company"), a special purpose acquisition company, announced today that the Company's stockholders have approved all proposals related to the previously announced business combination (the "Business Combination") with eFFECTOR Therapeutics, Inc. ("eFFECTOR") at a special meeting of stockholders held on August 24, 2021. Approximately 93.2% of the votes cast at the meeting on the Business Combination proposal, representing approximately 71.7% of LWAC's outstanding shares, voted to approve the Business Combination. LWAC stockholders also voted overwhelmingly to approve the other proposals

SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

3 - LightWave Acquisition Corp. (0002061379) (Issuer)

4 - LightWave Acquisition Corp. (0002061379) (Issuer)

3 - LightWave Acquisition Corp. (0002061379) (Issuer)